Type2 diabetes susceptible loci PPARγ2 is not associated with type1 diabetes at age of ~30 in Bangladeshi healthy people

Paper Details

Research Paper 01/04/2011
Views (930) Download (15)
current_issue_feature_image
publication_file

Type2 diabetes susceptible loci PPARγ2 is not associated with type1 diabetes at age of ~30 in Bangladeshi healthy people

Abdullah Al Emran, Farzana Ahmed
Int. J. Biosci.1( 2), 1-6, April 2011.
Certificate: IJB 2011 [Generate Certificate]

Abstract

Type 2 diabetes mellitus (T2DM) has become a global public health problem. In Bangladesh the disease has taken a turn of epidemic. This type of diabetes is known as silent killer disease affecting cardiovascular system especially heart and brain, eyes, kidney, nervous system and lower limbs. Genetic factors, sedentary habits, food habit and aging are the risk factors for the disease. In this study it was observed whether type 2diabetes susceptible loci PPARγ2 gene is associated with type 1diabetes. For this study 32 healthy male volunteers (age: 27±5) were included. Genomic DNA was extracted from the blood by Chelax method. For PPARγ2 Pro12Ala polymorphism analysis, PCR followed by Restriction digestion was done and subsequently products were visualized on 2% agarose gel after electrophoresis. Out of 32 subjects 26 (81.25%) were homozygous for Pro/Pro genotype, 6(11.75%) heterozygous for Pro/Ala heterozygous and none for Ala/Ala homozygous allele. No correlation between the polymorphism and age, BMI, systolic blood pressure, diastolic blood pressure, HDL cholesterol, LDL cholesterol, triglycerides, Random blood sugar, Glycosylated hemoglobin was observed. It can be concluded from the findings that, polymorphism in PPARγ2 gene is not associated with type 1diabetes and at the age group of ~30 it is not also associated with type 2 diabetes may be due to onset of type2 diabetes is above 40 age.

VIEWS 18

Ackert-Bicknell C, Rosen C. 2006. The Genetics of PPARG and the Skeleton. PPAR Res. 93258.

Altshuler D, Hirschhorn J, Klannemark M, Lindgren C M, Vohl M C, Nemesh J, Lane C R, Schaffner S F, Bolk S, Brewer C, Tuomi T, Gaudet D, Hudson T J, Daly M, Groop L, Lander ES.  2000.  The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nature Genetics 26, 76-80.

Atkinson and Maclaren, 1994. The pathogenesis of insulin-dependent diabetes mellitus. New England Journal of Medicine 331, 1428-36.

C Eftychi, JM Howson, BJ Barratt, A Vella, F Payne, DJ Smyth, RC Twells,  N.M. Walker, HE Rance, E Tuomilehto-Wolf, J Tuomilehto, DE Undlien, DA Savage, JA Todd. 2004. Analysis of the type 2 diabetes-  associated single nucleotide polymorphisms in the genes IRS1, KCNJ11, and PPARG2 in type 1 diabetes. Diabetes  53, 870–873.

Deeb  SS, Fajas L, Nemoto M, Kuusisto J, Laakso M, Fujimoto W, Auwerx JA.  1998. Pro12Ala substitution in PPAR γ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nature Genetics 20, 284-287.

Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R, Najib J, Laville M, Fruchart JC, Deeb S, Vidal-Puig  A, Flier J, Briggs MR, Staels BJ, Auwerx.  1997.  The organization, promoter analysis, and expression of the human  PPAR gamma gene.  Journal of Biological Chemistry 272, 18779-89.

Florez JC, Hirschhorn J, Altshuler D.  2003. The inherited basis of diabetes mellitus: implications for the genetic analysis of complex traits.  Annual Review Genomics Human Genetics 4, 257–291

Hara K, Okada T, Tobe K, Yasuda K, Mori Y, Kadowaki H, Hagura R, Akanuma Y, Kimura S, T Kadowaki. 2000. The Pro12Ala polymorphism in  PPAR gamma2 may confer resistance to type 2diabetes.  Biochemical and Biophysical Research Communication 271, 212-6.

Heikkinen S, Argmann C, Feige JN, Koutnikova H, Champy MF., Dali-Youcef N, Schadt EE, Laakso M,  Auwerx  J.  2009.  The Pro12Ala PPARgamma2  variant determines metabolism at the gene-environment  interface.  Cell Metabolism 9, 88-98.

Jacob S, Stumvoll M, Becker R, Koch M, Nielsen M,Loblein K., Maerker E, Volk A, Renn W, Balletshofer B, Machicao F, Rett K, Haring HU.  2000.  The PPAR gamma2 polymorphism Pro12Ala is associated with better insulin sensitivity in the offspring of type 2 diabetic patients. Hormone Metabolism Research 32, 413-416.

Johansen DP, Jensen R, Bergholdt HB, Mortensen F, Pociot J, Nerup.  2006.  IRS1, KCNJ11, PPARgamma2 and HNF-1alpha: do amino acid polymorphisms in these candidate genes supports shared aetiology between type 1 and type 2 diabetes? Diabetes Obesity Metabolism 8, 75–82.

King H, Aubert RE, Herman WH. 1998. Global burden of diabetes, 1995- 2025—prevalence, numerical estimates and projections. Diabetes Care 21, 1414-31.

Lovejoy JC .2002. The influence of dietary fat on insulin resistance. Current Diabetes Report.  2 (5), 435–40

Mancini FP, Vaccaro O, Sabatino L, Tufano A, Rivellese AA, Riccardi G, Colantuoni V.  1999. Pro12Ala substitution in the peroxisome proliferator-activated receptor-γ2 is not associated with type 2 diabetes. Diabetes 48, 1466-1468.

Mather HM, Keen H. 1985. The Southall Diabetes Survey: prevalence of known  diabetes in Asians and Europeans. British Medical Journal 291, 1081–1084.

Minamikawa J, Yamauchi M, Innoue D, Koshiyama H.  1998.  Another potential use of troglitazone in non-insulin dependent diabetes mellitus. Journal of Clinical Endocrinology Metabolism 83, 1041–1042.

Mori Y, Kim-Motoyama H, Katakura T, Yasuda K, Kadowaki H, Beamer BA, Shuldiner AR, AkanumaY, Yazaki Y, Kadowaki T.  1998. Effect of the Pro12Ala variant of the human peroxisome proliferator activated receptor γ2 gene on adiposity, fat distribution, and insulin sensitivity in Japanese men. Biochemical and Biophysical Research Communication 251, 195-198.

Rafiq S, Melzer D, Weedon MN.  2008.  Gene variants influencing measures of inflammation or predisposing to autoimmune and inflammatory diseases are not associated with the risk of type 2 diabetes. Diabetologia 51, 2205–2213.

Rahim MA, Hussain A, Azad Khan AK. 2007. Rising prevalence of type 2 diabetes in rural Bangladesh; a population based study. Diabetes Research Clinical Practice 77(2), 300-5.

Rahman MM, Rahim MA, Nahar.  2007. Prevalence and risk factor of type 2 diabetes in an urbanizing rural community of Bangladesh, Bangladesh Medical Research Council Bulletin 2, 48-54

Ringel J, Engeli S, Distler A, Sharma A M. 1999. Pro12Ala missense mutation of the peroxisome proliferator activated receptor γ and diabetes mellitus. Biochemical and Biophysical Research Communication 254, 450-453.

Werman A, Hollenberg A, Solanes G, Bjorbaek C, Vidal-Puig AJ,  Flier  JS.  1997.  Ligand-independent  activation domain in the N-terminus of peroxisome  proliferator-activated receptor gamma: Differential activity of PPAR gamma-1 and -2 isoforms and  influence of insulin.  Journal of Biological Chemistry 272, 20230-5.

Wilkin TJ. 2001. The accelerator hypothesis: weight gain as the missing link between type I and type II diabetes. Diabetologia 44, 914-922.

Yen CJ, Beamer BA, Negri C, Silver K, Brown KA, Yarnall DP, Burns DK, Roth J, Shuldiner. 1997. Molecular scanning of the human peroxisome  proliferator activated receptor gamma (hPPAR gamma)  gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Bio. & Bioph. R. Com. 241, 270-4.

Zietz B, Barth N, Spielgel D, Schmitz G. 2002. Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-γ2 (PPARγ2) is associated with higher levels of total cholesterol and LDL cholesterol in male caucasian type 2 diabetes patients.  Experimental  Clinical Endocrinology Diabetes 110, 60-66.